USANA Health Sciences, Inc. ($USNA) - Quick Stock Analysis | Summary and Q&A

TL;DR

Usana Health Sciences is a slow-growing company with a market cap of $1.7 billion, consistent profit growth, high insider ownership, and strong financials.

Key Insights

• 🐢 Usana Health Sciences is a slow-growing company with low revenue growth over the past five years.
• ❓ The company's profit growth has been consistent but not significant.
• 🥹 The presence of 40% insider-held stocks indicates strong alignment between insiders' goals and shareholders' interests.
• 💪 Usana Health Sciences has strong financials, with more current assets than current and total liabilities.
• 🧑‍⚕️ With a market cap of $1.7 billion, Usana Health Sciences is in the health and wellness industry.
• ❓ The company's financials suggest it may be undervalued, but a more detailed analysis is necessary to account for nuances.
• ↩️ The expected return on investment for Usana Health Sciences is around 10%.

Transcript

Read and summarize the transcript of this video on Glasp Reader (beta).

Questions & Answers

Q: What is the market cap of Usana Health Sciences?

Usana Health Sciences has a market cap of $1.7 billion.

Q: Has the company shown consistent profit growth?

Yes, the company has consistently grown its profits over the last five years, although not at a significant rate.

Q: Why is insider ownership important for investors?

Insider ownership is important because it shows that the company's insiders have a vested interest in the company's success and are more likely to work towards improving it.

Q: How do Usana Health Sciences' financials look?

The company has strong financials, with current assets of $386 million and current liabilities of $160 million, indicating a healthy financial position.

Q: What is the expected return on investment for Usana Health Sciences?

Based on the analysis, an expected return of 10% is suggested, which translates to a price range of $44 to $60 per share.

Summary & Key Takeaways

• Usana Health Sciences has a market cap of $1.7 billion, a PE ratio of 14.74, and a profit margin of 10.22%. However, its revenue growth over the past five years has been slow.

• The company's profit growth over the last five years has been consistent but not significant, showing a growth from 95 to 100.

• Usana Health Sciences has 40% insider-held stocks, indicating strong alignment between insiders and shareholders' interests.

• The company has strong financials, with current assets of $386 million, current liabilities of $160 million, and total liabilities of $188 million. Deducting the total liabilities, the market cap reduces to $1.45 billion.